Rituximab for the treatment of patients with autoimmune hepatitis who are refractory or intolerant to standard therapy
about
Risk and Surveillance of Cancers in Primary Biliary Tract DiseaseAutoimmune Hepatitis: Progress from Global Immunosuppression to Personalised Regulatory T Cell TherapyBrazilian society of hepatology recommendations for the diagnosis and management of autoimmune diseases of the liverReview article: permanent drug withdrawal is desirable and achievable for autoimmune hepatitisManagement of autoimmune hepatitis: Focus on pharmacologic treatments beyond corticosteroidsReview article: chemokines as orchestrators of autoimmune hepatitis and potential therapeutic targetsImmunopathogenic Mechanisms of Autoimmune Hepatitis: How Much Do We Know from Animal Models?Diagnosis and Management of Autoimmune Hepatitis: Current Status and Future DirectionsNovel Immunotherapies for Autoimmune Hepatitis.Challenges in the diagnosis and management of autoimmune hepatitis.The use of immunosuppression in autoimmune hepatitis: A current literature reviewReview article: The prevention and reversal of hepatic fibrosis in autoimmune hepatitis.Current and prospective pharmacotherapy for autoimmune hepatitis.Cell mediators of autoimmune hepatitis and their therapeutic implications.Autoimmune hepatitis: an approach to disease understanding and management.Autoimmune hepatitis: Unveiling faces.Evolving paradigm of treatment for autoimmune hepatitis.Expert clinical management of autoimmune hepatitis in the real world.Review article: next-generation transformative advances in the pathogenesis and management of autoimmune hepatitis.Long-term follow-up of patients with difficult to treat type 1 autoimmune hepatitis on Tacrolimus therapy.B cells expressing CD11b effectively inhibit CD4+ T-cell responses and ameliorate experimental autoimmune hepatitis in mice."Autoimmune(-Like)" Drug and Herb Induced Liver Injury: New Insights into Molecular Pathogenesis.Autoimmune hepatitis: Standard treatment and systematic review of alternative treatments.Refractory Autoimmune Hepatitis: Beyond Standard Therapy.High affinity anti-BSEP antibodies after liver transplantation for PFIC-2 - Successful treatment with immunoadsorption and B-cell depletion.Changes in natural killer cells and exhausted memory regulatory T Cells with corticosteroid therapy in acute autoimmune hepatitis.B-cell depletion in autoimmune hepatitis: Is it safe for the bowel?Anti-drug Antibodies Against a Novel Humanized Anti-CD20 Antibody Impair Its Therapeutic Effect on Primary Biliary Cholangitis in Human CD20- and FcγR-Expressing Mice
P2860
Q26740434-C7D9AAAB-A9BE-4585-BB38-7305C8FFCFAAQ26742101-52B8694E-B2DB-494C-B142-9CDA16602E0DQ26766699-ACCF0A1C-521E-4C41-A49E-E4FBE8894ACDQ26827599-40DC9F2B-8D53-432B-9FA8-B57556E2B4DCQ26859099-18929DBF-D8AF-48E4-94B0-D79B137908DAQ27025680-3F99C6EF-A301-4143-8AE8-A67BC328E05FQ28069584-5E80101D-EE29-4278-A71D-786C431F9B9DQ28076505-D99A8630-23F4-4025-AF62-176FD414FC5FQ37607111-FFFC7ECD-79E1-4F7E-856E-5D408918F097Q37640582-83BDC829-71EA-457F-902A-9A4D9B2D3AF8Q37738804-9071EB5F-68BA-4E43-A7A7-9326EE75D6D9Q38175465-4A1A2169-BB7A-4D0A-8751-2E20321C87FFQ38222882-7D08D555-CF12-4CB9-918B-A2BDA58BFE13Q38285331-52677EBA-39AC-47B8-9B4A-920A12D1A2BAQ38494826-FD310A6A-9919-4EBA-A3BD-9C758EB3173CQ38579048-6390DA59-026E-4DB5-9A55-D0DC1302B505Q38730872-B9DD85A2-7BD0-41B8-B36C-57A78641E97EQ38779430-68F66237-F533-4733-B639-14B337EEA53EQ40044046-04D6A440-498B-4595-A122-83C7322AD48FQ40441464-59C35A22-6749-4BF6-8EEC-2A5DE2D6A832Q41551818-0FE6A44A-27CB-479A-A2D6-1118EF34265FQ41660660-E539184C-DDFD-45C2-A21E-70B496F9576CQ42358509-D44B3D8B-8AED-4376-BDFF-83D243634FA9Q46408372-25ED1E70-4355-4F86-A848-808B5FB2FAD6Q51668984-1BBDFF6B-C5AE-4427-B5C8-8414BFADED51Q52605836-6A023A11-93B1-44D1-A709-EF32524D4AD4Q53779805-CA9A7C9E-9327-42AB-9306-65EA504D19A3Q59137473-9B01549B-9671-4021-AC76-C69507580225
P2860
Rituximab for the treatment of patients with autoimmune hepatitis who are refractory or intolerant to standard therapy
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on January 2013
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Rituximab for the treatment of ...... intolerant to standard therapy
@en
Rituximab for the treatment of ...... ntolerant to standard therapy.
@nl
type
label
Rituximab for the treatment of ...... intolerant to standard therapy
@en
Rituximab for the treatment of ...... ntolerant to standard therapy.
@nl
prefLabel
Rituximab for the treatment of ...... intolerant to standard therapy
@en
Rituximab for the treatment of ...... ntolerant to standard therapy.
@nl
P2093
P2860
P356
P1476
Rituximab for the treatment of ...... intolerant to standard therapy
@en
P2093
Carla S Coffin
Kelly W Burak
Mark G Swain
Robert P Myers
Samuel S Lee
Stefan J Urbanski
Tania Santodomingo-Garzon
P2860
P304
P356
10.1155/2013/512624
P407
P577
2013-01-01T00:00:00Z